Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
[HTML][HTML] The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
S Ghalehbandi, J Yuzugulen, MZI Pranjol… - European Journal of …, 2023 - Elsevier
Angiogenesis is a double-edged sword; it is a mechanism that defines the boundary
between health and disease. In spite of its central role in physiological homeostasis, it …
between health and disease. In spite of its central role in physiological homeostasis, it …
[HTML][HTML] Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
JH Strickler, H Satake, TJ George… - New England journal …, 2023 - Mass Medical Soc
Abstract Background KRAS p. G12C mutation occurs in approximately 1 to 2% of pancreatic
cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated …
cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously treated …
Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion
W Tian, N Lei, J Zhou, M Chen, R Guo, B Qin, Y Li… - Cell Death & …, 2022 - nature.com
Chemoresistance and metastasis are the major challenges for the current ovarian cancer
treatment. Understanding the mechanisms of ovarian cancer progression and metastasis is …
treatment. Understanding the mechanisms of ovarian cancer progression and metastasis is …
DNA damage response in cancer therapy and resistance: challenges and opportunities
D Jurkovicova, CM Neophytou, AČ Gašparović… - International Journal of …, 2022 - mdpi.com
Resistance to chemo-and radiotherapy is a common event among cancer patients and a
reason why new cancer therapies and therapeutic strategies need to be in continuous …
reason why new cancer therapies and therapeutic strategies need to be in continuous …
Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
A Ragupathi, M Singh, AM Perez… - Frontiers in Cell and …, 2023 - frontiersin.org
BRCA1 and BRCA2 play a critical role in a variety of molecular processes related to DNA
metabolism, including homologous recombination and mediating the replication stress …
metabolism, including homologous recombination and mediating the replication stress …
Differences in PARP inhibitors for the treatment of ovarian cancer: mechanisms of action, pharmacology, safety, and efficacy
G Valabrega, G Scotto, V Tuninetti, A Pani… - International journal of …, 2021 - mdpi.com
Poly (ADP-ribose) polymerases (PARP) are proteins responsible for DNA damage detection
and signal transduction. PARP inhibitors (PARPi) are able to interact with the binding site for …
and signal transduction. PARP inhibitors (PARPi) are able to interact with the binding site for …
Targeting HIF-2α in the tumor microenvironment: redefining the role of HIF-2α for solid cancer therapy
Simple Summary Hypoxia is defined as the inadequate supply of oxygen in tissues. Regions
of acute and chronic hypoxia are a universal feature of the tumor microenvironment and a …
of acute and chronic hypoxia are a universal feature of the tumor microenvironment and a …
[HTML][HTML] Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials
DK Nambiar, D Mishra, RP Singh - Oncology research, 2023 - ncbi.nlm.nih.gov
Ionizing radiation is frequently used to treat solid tumors, as it causes DNA damage and kill
cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 …
cancer cells. However, damaged DNA is repaired involving poly-(ADP-ribose) polymerase-1 …
Changing landscape of anti-angiogenic therapy: Novel approaches and clinical perspectives
RN Gacche - Biochimica et Biophysica Acta (BBA)-Reviews on …, 2023 - Elsevier
Targeting angiogenesis has remained one of the important aspects in disease biology in
general and cancer in particular. Currently (June 2023), over 593 clinical trials have been …
general and cancer in particular. Currently (June 2023), over 593 clinical trials have been …